S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
NYSE:BLCO

Bausch + Lomb - BLCO Stock Forecast, Price & News

$17.29
-0.23 (-1.31%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$17.22
▼
$17.68
50-Day Range
$14.54
▼
$17.52
52-Week Range
$12.20
▼
$20.20
Volume
493,988 shs
Average Volume
211,452 shs
Market Capitalization
$6.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

Bausch + Lomb MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
27.2% Upside
$22.00 Price Target
Short Interest
Bearish
15.65% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.87mentions of Bausch + Lomb in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-4.76%
From $1.05 to $1.00 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.47 out of 5 stars

Medical Sector

938th out of 1,028 stocks

Ophthalmic Goods Industry

6th out of 7 stocks

See Top Rated MarketRank™ Stocks Here
BLCO stock logo

About Bausch + Lomb (NYSE:BLCO) Stock

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.

Receive BLCO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch + Lomb and its competitors with MarketBeat's FREE daily newsletter.

BLCO Stock News Headlines

February 1, 2023 | wsj.com
Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb's VISUDYNE(R) (Verteporfin for Injection)
February 1, 2023 | finance.yahoo.com
Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE® (Verteporfin for Injection)
February 5, 2023 | Wall Street Watch Dogs (Ad)
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
January 24, 2023 | seekingalpha.com
Bausch + Lomb: Still A Favorable Risk-To-Reward Prospect
January 23, 2023 | finance.yahoo.com
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2022 Financial Results on February 22
January 17, 2023 | finance.yahoo.com
Bausch + Lomb Acquires AcuFocus, Inc.
January 13, 2023 | theglobeandmail.com
Bausch & Lomb: Top 25 Undervalued Dividend Stocks on TSX (BLCO)
January 9, 2023 | finance.yahoo.com
Bausch + Lomb Publishes Update Presentation for the 41st Annual J.P. Morgan Healthcare Conference
February 5, 2023 | Wall Street Watch Dogs (Ad)
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
January 9, 2023 | finance.yahoo.com
Bausch + Lomb Introduces Enhanced PreserVision® AREDS 2 Formula Mini Soft Gels with OCUSorb™
January 5, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV) and Bausch + Lomb Corporation (BLCO)
January 5, 2023 | finance.yahoo.com
Bausch + Lomb Announces Participation at the 41st Annual J.P. Morgan Healthcare Conference
January 4, 2023 | finance.yahoo.com
Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology
January 3, 2023 | finance.yahoo.com
Bausch + Lomb and Glaucoma Research Foundation Announce Launch of Screen, Protect, Cure Campaign In Recognition of Glaucoma Awareness Month
December 27, 2022 | finance.yahoo.com
Implied Volatility Surging for Bausch + Lomb (BLCO) Stock Options
December 22, 2022 | finance.yahoo.com
Bausch + Lomb Amends CEO Separation Agreement
December 21, 2022 | benzinga.com
7 Analysts Have This to Say About Bausch & Lomb
December 13, 2022 | finance.yahoo.com
Bausch + Lomb Receives 510(k) Clearance from FDA for Biotrue® Hydration Boost Contact Lens Rehydrating Drops
December 12, 2022 | finance.yahoo.com
Bausch + Lomb's ONE by ONE and Biotrue® Eye Care Recycling Programs Win Gold for Most Environmentally Friendly Service of the Year from Best in Biz Awards
November 29, 2022 | finance.yahoo.com
Bausch + Lomb's Biotrue® Hydration Plus Multi-Purpose Solution Receives Product of the Year Award from Business Intelligence Group's 2022 BIG Awards for Business
November 23, 2022 | markets.businessinsider.com
What 7 Analyst Ratings Have To Say About Bausch & Lomb
November 15, 2022 | finance.yahoo.com
Bausch + Lomb Reports More Than 58 Million Units of Contact Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs
November 9, 2022 | seekingalpha.com
Bausch + Lomb: A Solid Play In Challenging Economic Times
November 7, 2022 | finance.yahoo.com
Bausch + Lomb Announces Participation at the 5th Annual Evercore ISI HealthCONx Conference
November 6, 2022 | seekingalpha.com
Bausch + Lomb Corporation (BLCO) Q3 2022 Earnings Call Transcript
November 4, 2022 | cnbc.com
4 of our stocks are in the news. Here's the Club's take on each development
November 2, 2022 | markets.businessinsider.com
Bausch + Lomb Announces Third-Quarter 2022 Results
See More Headlines
Receive BLCO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch + Lomb and its competitors with MarketBeat's FREE daily newsletter.

BLCO Company Calendar

Today
2/05/2023
Next Earnings (Confirmed)
2/22/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Ophthalmic goods
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:BLCO
CUSIP
N/A
CIK
1860742
Web
www.bausch.com
Phone
905-695-7700
Fax
N/A
Employees
12,500
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.00
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+21.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
15 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
16.47
P/E Growth
1.77
Net Income
$182 million
Net Margins
1.54%
Pretax Margin
4.27%
Return on Equity
4.59%
Return on Assets
3.21%

Debt

Debt-to-Equity Ratio
0.36
Current Ratio
1.55
Quick Ratio
1.05

Sales & Book Value

Annual Sales
$3.77 billion
Price / Sales
1.61
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
350,000,000
Free Float
N/A
Market Cap
$6.05 billion
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Joseph C. Papa (Age 67)
    CEO & Director
    Comp: $4.08M
  • Mr. Osama A. Eldessouky (Age 51)
    Exec. VP & CFO
    Comp: $1.37M
  • Ms. Christina M. Ackermann (Age 58)
    Exec. VP, Gen. Counsel & Pres of Ophthalmic Pharmaceuticals
    Comp: $1.63M
  • Mr. Joseph F. Gordon (Age 58)
    Pres of Global Consumer, Surgical & Vision Care
    Comp: $1.36M
  • Ms. Kelly Webber
    Exec. VP & Chief HR Officer
  • Dr. Yehia Hashad M.D. (Age 56)
    Exec. VP of R&D and Chief Medical officer
  • Mr. Louis W. Yu (Age 73)
    Exec. VP & Chief Quality Officer
  • Mr. Dennis Asharin
    Exec. VP and Chief Global Manufacturing & Supply Chain Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions













BLCO Stock - Frequently Asked Questions

Should I buy or sell Bausch + Lomb stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bausch + Lomb in the last twelve months. There are currently 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BLCO shares.
View BLCO analyst ratings or view top-rated stocks.

What is Bausch + Lomb's stock price forecast for 2023?

15 brokerages have issued twelve-month price objectives for Bausch + Lomb's stock. Their BLCO share price forecasts range from $15.00 to $35.00. On average, they anticipate the company's stock price to reach $22.00 in the next year. This suggests a possible upside of 27.2% from the stock's current price.
View analysts price targets for BLCO or view top-rated stocks among Wall Street analysts.

How have BLCO shares performed in 2023?

Bausch + Lomb's stock was trading at $15.51 at the start of the year. Since then, BLCO shares have increased by 11.5% and is now trading at $17.29.
View the best growth stocks for 2023 here.

Are investors shorting Bausch + Lomb?

Bausch + Lomb saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 6,020,000 shares, an increase of 57.2% from the December 31st total of 3,830,000 shares. Based on an average trading volume of 437,600 shares, the days-to-cover ratio is presently 13.8 days. Approximately 15.7% of the shares of the company are sold short.
View Bausch + Lomb's Short Interest.

When is Bausch + Lomb's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our BLCO earnings forecast.

How can I listen to Bausch + Lomb's earnings call?

Bausch + Lomb will be holding an earnings conference call on Wednesday, February 22nd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 919-882-2331 with passcode "47443".

What guidance has Bausch + Lomb issued on next quarter's earnings?

Bausch + Lomb updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $3.70 billion-$3.75 billion.

When did Bausch + Lomb IPO?

(BLCO) raised $788 million in an initial public offering (IPO) on Friday, May 6th 2022. The company issued 35,000,000 shares at $21.00-$24.00 per share.

What is Bausch + Lomb's stock symbol?

Bausch + Lomb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BLCO."

Who are Bausch + Lomb's major shareholders?

Bausch + Lomb's stock is owned by many different retail and institutional investors. Top institutional shareholders include River Road Asset Management LLC (0.47%), Segantii Capital Management Ltd (0.14%), Hodges Capital Management Inc. (0.14%), Wolverine Asset Management LLC (0.02%), Illinois Municipal Retirement Fund (0.01%) and Renaissance Capital LLC (0.00%).

How do I buy shares of Bausch + Lomb?

Shares of BLCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bausch + Lomb's stock price today?

One share of BLCO stock can currently be purchased for approximately $17.29.

How much money does Bausch + Lomb make?

Bausch + Lomb (NYSE:BLCO) has a market capitalization of $6.05 billion and generates $3.77 billion in revenue each year.

How many employees does Bausch + Lomb have?

The company employs 12,500 workers across the globe.

How can I contact Bausch + Lomb?

The official website for the company is www.bausch.com. The company can be reached via phone at 905-695-7700.

This page (NYSE:BLCO) was last updated on 2/5/2023 by MarketBeat.com Staff